av/in8bio-inc--big.svg

NASDAQ:INAB

IN8bio, Inc.

  • Stock

0.17

+0.53%

−2.12

USD last updated 14/08 01:46:41

Last Close

2.29

13/08 20:00

Market Cap

37.34M

Beta: -

Volume Today

484.98K

Avg: 3.83M

PE Ratio

−1.32

PFCF: −1.90

OverviewFinancialsAPI

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

    Description

    IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; a...Show More

    Excel Tearsheet

    Earnings

    Earnings per Share (Estimate*)

    -0.5-0.4-0.3-0.2-0.12018-03-302019-06-302021-03-312023-03-302024-04-04

    Revenue (Estimate*)

    0.000.000.010.010.012018-03-302019-06-302021-03-312023-03-302024-04-04

    *Estimate based on analyst consensus